We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Death Risk of Heart Failure Patients

By HospiMedica staff writers
Posted on 28 Feb 2005
A new practical tool has been developed to predict the high, intermediate, and low risk of death in hospitalized heart failure patients, using two simple blood tests and a single blood pressure measurement.

Investigators used a type of statistical analysis known as CART (classification and regression tree) to analyze a number of clinical variables in order to develop a tool to assess mortality risk in heart failure patients. More...
From an observational evaluation of 39 clinical variables from more than 65,000 hospitalized heart failure patients, they were able to define three clinical characteristics that put patients at greatest risk of mortality. These are high levels of blood urea nitrogen (BUN greater or equal to mg/dl), low systolic blood pressure (SBP > 115 mm HG), and high serum creatinine (Cr greater than or equal to 2.75 mg/dl). The validity of this tool was tested using data from an additional 32,229 hospitalizations.

The overall mortality risk for patients hospitalized with acute heart failure was 4.1%. The new tool determined mortality risk levels starting from low risk at 2.1% up to 21.9% for patients with the highest risk. Clyde W. Yancy, M.D., professor of medicine and cardiology at the University of Texas Southwestern Medical Center (Dallas, USA; www.swmed.edu) was a contributing investigator of the study.

"This new tool is a first for the treatment of acute decompensated heart failure, and offers a simple quick way for clinicians to assess mortality risk upon hospital admission and rapidly decide on a treatment strategy,” noted Gregg C. Fonarow, M.D., professor of medicine in the division of cardiology at the University of California, Los Angeles (USA).

The study was conducted by investigators from the world's largest heart failure registry, known as ADHERE (acute decompensated heart failure), sponsored by Scios, Inc. (San Francisco, CA, USA). The study was published in the February 2, 2005, issue of the Journal of the American Medical Association.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.